Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RLMD vs SGMO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
RLMD Captures Overall Composite Edge (35.3 SELL vs 52.0 HOLD), While SGMO Leads 3–2 on Growth & Valuation Pillars
RLMD Overall Winner
6-Pillar Tally: RLMD 2 – 3 SGMO (1 Tie)
Matrix Metrics: RLMD 5 – 4 SGMO
As of Nov 16, 2026, Relmada Therapeutics, Inc. (RLMD) captures the overall head-to-head institutional edge over Sangamo Therapeutics, Inc. (SGMO) on higher Unified Composite conviction (35.3/100 SELL vs. 52.0/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while SGMO wins 3–2 across the 6-pillar growth and valuation breakdown. RLMD trades at $3.62 (N/M Forward P/E, 0.0% operating margin) versus SGMO at $0.18 (0.4x Forward P/E, -175.5% operating margin).
- Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. RLMD 35.3/100 SELL), RLMD captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY).
- Technical & Structure Timing Caution: RLMD is currently in a Breakdown options structure phase (RSI 45.9); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About RLMD vs SGMO
RLMD
Head-to-Head Winner
Relmada Therapeutics, Inc. Common Stock
$3.62
-14.01% 1D
Market Cap
$421.3M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.58β · 93% Vol
Unified Composite Score
35.3
SELL
Tech 50.0
Fund 34.0
Flow 71.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
SGMO
Sangamo Therapeutics, Inc. Common Stock
$0.18
+31.56% 1D
Market Cap
$55.9M
TTM Revenue
$40M
Forward P/E
0.4x
Beta / 30D Vol
1.49β · 206% Vol
Unified Composite Score
52.0
HOLD
Tech 25.0
Fund 46.0
Flow 65.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (RLMD 2 – 3 SGMO)
1. Valuation Multiples
SGMO
Forward P/E
N/M
0.4x
Trailing P/E
N/M
0.4x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
1.2x
2. Growth & Scale
SGMO
Revenue Growth (YoY)
+0.0%
+88.4%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$40M
Market Cap
$421.3M
$55.9M
3. Profitability & Quality
RLMD
Gross Margin
N/A
N/A
Operating Margin
0.0%
-175.5%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-64.7%
-2891.8%
4. Balance Sheet & Cash Flow
SGMO
Cash Generation (TTM)
-$46M
-$90M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.94 Book/Sh · -64.7% ROE
$8.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RLMD
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
93.2% (36th %ile)
144.2% (71st %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
N/A
OBV Trend / Tech Phase
ACCUMULATION · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: RLMD (5) vs SGMO (4)| Institutional Metric | RLMD | SGMO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $421.3M | $55.9M | RLMD | |
| Trailing P/E Ratio | N/M | 0.4x | SGMO | |
| Forward P/E Ratio | N/M | 0.4x | SGMO | |
| Revenue Growth (YoY) | +0.0% | +88.4% | SGMO | |
| Operating Margin (TTM) | 0.0% | -175.5% | RLMD | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -64.7% | -2891.8% | RLMD | |
| 52-Week Range Position | 11% ($3–$8) | 9% ($0–$1) | RLMD | |
| Beta / 30D Volatility | 1.58β · 93% Vol | 1.49β · 206% Vol | RLMD | |
| Unified Institutional Score | 35.3 / 100 (SELL) | 52.0 / 100 (HOLD) | SGMO | |
| Trailing 12M Revenue (USD) | N/A | $40M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 1.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$46M ($1.94 Book/Sh · -64.7% ROE) | -$90M ($8.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
RLMD +46.83 pp
3M Horizon
RLMD +162.2 pp
6M Horizon
RLMD +151.44 pp
1Y Horizon
RLMD +151.44 pp
Financial Trajectory Multi-Year Revenue & Operating Margin Trajectory (USD)
| Period | RLMD Revenue | SGMO Revenue | RLMD Op. Margin | SGMO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2012 | $0M | N/A | -151.8% | N/A | RLMD |
| FY2013 | $0M | N/A | -877.7% | N/A | RLMD |
| Q1 '25 | N/A | $30M | N/A | -460.3% | SGMO |
| Q1 '26 | N/A | $10M | N/A | -2215.4% | SGMO |
| Q2 '25 | N/A | $70M | N/A | -97.5% | SGMO |
| Q3 '25 | N/A | $0M | N/A | -6119.3% | SGMO |
| Q4 '25 | N/A | $60M | N/A | -175.5% | SGMO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
RLMD
BREAKDOWN
Current IV
93.2%
IV Percentile
36th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact RLMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
SGMO
UNCLASSIFIED
Current IV
144.2%
IV Percentile
71st %ile
Put/Call OI Skew
N/A
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact SGMO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
RLMD Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
SGMO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ RLMD vs SGMO Key Questions & Quantitative Answers
As of Nov 16, 2026, Relmada Therapeutics, Inc. (RLMD) captures the overall head-to-head institutional edge over Sangamo Therapeutics, Inc. (SGMO) on higher Unified Composite conviction (35.3/100 SELL vs. 52.0/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality, Options & Positioning), while SGMO wins 3–2 across the 6-pillar growth and valuation breakdown. RLMD trades at $3.62 (N/M Forward P/E, 0.0% operating margin) versus SGMO at $0.18 (0.4x Forward P/E, -175.5% operating margin). Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. RLMD 35.3/100 SELL), RLMD captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY). Technical & Structure Timing Caution: RLMD is currently in a Breakdown options structure phase (RSI 45.9); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SGMO leads the Growth & Scale pillar: RLMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SGMO at +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin). Across the 7-period historical trajectory (FY2012 to Q4 '25), RLMD cumulative revenue shifted N/A while SGMO shifted +100.0%. In operating R&D and SG&A reinvestment, RLMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMO.
SGMO screens cheaper on headline valuation multiples. RLMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RLMD (-64.7% ROE) versus SGMO (-2891.8% ROE) capital efficiency.
In options market volatility and institutional positioning, RLMD carries 93.2% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 93% Vol realized risk). By comparison, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
SGMO vs RLMD · Reverse Pair
RLMD vs STOK
· Sector Peer
RLMD vs FULC
· Sector Peer
RLMD vs PHAT
· Sector Peer
SGMO vs LAZR
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma